[
  {
    "ts": null,
    "headline": "Barclays Flags Medtronic, J&J as Most at Risk from Looming Pharma Tariffs",
    "summary": "Barclays outlines which MedTech stocks could feel the most pressure from Trump's anticipated global pharmaceutical tariffs",
    "url": "https://finnhub.io/api/news?id=ee2e446590c0792f2ccb86f61c03eea1271aa171ba94ac8f196d4d1b1a2cf4bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744837003,
      "headline": "Barclays Flags Medtronic, J&J as Most at Risk from Looming Pharma Tariffs",
      "id": 133942555,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Barclays outlines which MedTech stocks could feel the most pressure from Trump's anticipated global pharmaceutical tariffs",
      "url": "https://finnhub.io/api/news?id=ee2e446590c0792f2ccb86f61c03eea1271aa171ba94ac8f196d4d1b1a2cf4bc"
    }
  },
  {
    "ts": null,
    "headline": "Hertz, Abbott Laboratories, and Interactive Brokers: Trending tickers",
    "summary": "Josh Lipton, joined by Defiance ETFs CEO and chief investment officer Sylvia Jablonski, examines some of the trading day's trending tickers. Hertz (HTZ) shares pop after Bill Ackman-led Pershing Square Capital Management disclosed a stake of 12.7 million shares of the rental car company's stock. Abbott Laboratories (ABT) gained after the medical tech company reported stronger-than-expected earnings. Interactive Brokers (IBKR) tumbles after earnings results missed analyst estimates. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=44a66fb21639a0134acdcf84d93b9ecc5a8634caf406c325f0074a0900dd9d7b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744834209,
      "headline": "Hertz, Abbott Laboratories, and Interactive Brokers: Trending tickers",
      "id": 133942556,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Josh Lipton, joined by Defiance ETFs CEO and chief investment officer Sylvia Jablonski, examines some of the trading day's trending tickers. Hertz (HTZ) shares pop after Bill Ackman-led Pershing Square Capital Management disclosed a stake of 12.7 million shares of the rental car company's stock. Abbott Laboratories (ABT) gained after the medical tech company reported stronger-than-expected earnings. Interactive Brokers (IBKR) tumbles after earnings results missed analyst estimates. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=44a66fb21639a0134acdcf84d93b9ecc5a8634caf406c325f0074a0900dd9d7b"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Makes A Bullish Move, Shrugging Off Covid Test Malaise",
    "summary": "Abbott stock jumped Wednesday despite a mixed first-quarter report thanks to light sales of its Covid tests.",
    "url": "https://finnhub.io/api/news?id=b92eb6f525bd4078df008c0bc9bb6f5589078d94f21e7c4773d1b11bc2897233",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744833859,
      "headline": "Abbott Makes A Bullish Move, Shrugging Off Covid Test Malaise",
      "id": 133942557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott stock jumped Wednesday despite a mixed first-quarter report thanks to light sales of its Covid tests.",
      "url": "https://finnhub.io/api/news?id=b92eb6f525bd4078df008c0bc9bb6f5589078d94f21e7c4773d1b11bc2897233"
    }
  },
  {
    "ts": null,
    "headline": "Is Abbott Laboratories (ABT) the Best Dividend Monarch to Invest in Now?",
    "summary": "We recently published a list of the 10 Best Dividend Monarchs to Invest in Now. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other best dividend monarchs. Dividend-focused investors are generally well-acquainted with terms like Dividend Aristocrats and Dividend Kings, but many may not be aware […]",
    "url": "https://finnhub.io/api/news?id=5cee36df53ac59e8df4acddfe4b63aa50adf4f2f6bbbe9cdd1e6b9925190d4d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744832978,
      "headline": "Is Abbott Laboratories (ABT) the Best Dividend Monarch to Invest in Now?",
      "id": 133942558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "We recently published a list of the 10 Best Dividend Monarchs to Invest in Now. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other best dividend monarchs. Dividend-focused investors are generally well-acquainted with terms like Dividend Aristocrats and Dividend Kings, but many may not be aware […]",
      "url": "https://finnhub.io/api/news?id=5cee36df53ac59e8df4acddfe4b63aa50adf4f2f6bbbe9cdd1e6b9925190d4d3"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs Stock Jumps on Strong Earnings, With $500M Investment in US Facilities",
    "summary": "Abbott Laboratories shares surged Wednesday after the medical device maker said it plans to invest $500 million in U.S. operations and topped Wall Street’s expectations with its first-quarter results.",
    "url": "https://finnhub.io/api/news?id=d9ae80cc9fd061e4f6a260a477af455726d3b82c265cd4af9214162447daf12e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744827076,
      "headline": "Abbott Labs Stock Jumps on Strong Earnings, With $500M Investment in US Facilities",
      "id": 133942559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories shares surged Wednesday after the medical device maker said it plans to invest $500 million in U.S. operations and topped Wall Street’s expectations with its first-quarter results.",
      "url": "https://finnhub.io/api/news?id=d9ae80cc9fd061e4f6a260a477af455726d3b82c265cd4af9214162447daf12e"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (NYSE:ABT) Reports Q1 Sales And Income Growth With Earnings At US$0.76",
    "summary": "Abbott Laboratories (NYSE:ABT) recently reported positive Q1 2025 results, showing increased sales and net income, which may have bolstered its share price by 14% last quarter. The enhanced financial performance, including a rise in diluted EPS, highlighted profitability improvements. This, coupled with ongoing stock buybacks and a longstanding commitment to dividends, likely contributed to investor confidence. Despite broader market concerns such as U.S.-China trade tensions impacting tech...",
    "url": "https://finnhub.io/api/news?id=50bb4aceeadc69b13b712e75f997b56c3e185230d8ccbb360731636be44fb037",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744825173,
      "headline": "Abbott Laboratories (NYSE:ABT) Reports Q1 Sales And Income Growth With Earnings At US$0.76",
      "id": 133942560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) recently reported positive Q1 2025 results, showing increased sales and net income, which may have bolstered its share price by 14% last quarter. The enhanced financial performance, including a rise in diluted EPS, highlighted profitability improvements. This, coupled with ongoing stock buybacks and a longstanding commitment to dividends, likely contributed to investor confidence. Despite broader market concerns such as U.S.-China trade tensions impacting tech...",
      "url": "https://finnhub.io/api/news?id=50bb4aceeadc69b13b712e75f997b56c3e185230d8ccbb360731636be44fb037"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Stays Ahead of Market Amid Defensive Bias - Health Care Roundup",
    "summary": "Health Care Stays Ahead of Market Amid Defensive Bias - Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=db9bf82bf03e4a8633a7607f02d28c2752e452d7d2644703c4f49a83dd47b9cd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744824000,
      "headline": "Health Care Stays Ahead of Market Amid Defensive Bias - Health Care Roundup",
      "id": 133946283,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Health Care Stays Ahead of Market Amid Defensive Bias - Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=db9bf82bf03e4a8633a7607f02d28c2752e452d7d2644703c4f49a83dd47b9cd"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Q1 Earnings Beat, Sales Miss, Stock Falls in Pre-Market",
    "summary": "ABT delivers a strong underlying base business performance for the first quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=f537f287490278017352fa85c995d35c9b8b005a8c3d3be37f78d12a3e6075c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744823220,
      "headline": "Abbott Q1 Earnings Beat, Sales Miss, Stock Falls in Pre-Market",
      "id": 133942561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "ABT delivers a strong underlying base business performance for the first quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=f537f287490278017352fa85c995d35c9b8b005a8c3d3be37f78d12a3e6075c0"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Health Care Roundup: Market Talk",
    "url": "https://finnhub.io/api/news?id=b1cc2c45676596ec22fdfd94c3dad8a10c7a308d11066835a9863fa446f50e71",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744822740,
      "headline": "Health Care Roundup: Market Talk",
      "id": 133946263,
      "image": "",
      "related": "ABT",
      "source": "DowJones",
      "summary": "Health Care Roundup: Market Talk",
      "url": "https://finnhub.io/api/news?id=b1cc2c45676596ec22fdfd94c3dad8a10c7a308d11066835a9863fa446f50e71"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs Bracing for Tariffs as Profits Rise",
    "summary": "Abbott Labs boosted its earnings in the first quarter and hinted that its full-year guidance might have gotten a lift were it not for looming cost hikes from the recent tariff war.",
    "url": "https://finnhub.io/api/news?id=07cd7701c08de84256ccffcfdb178181affbe3c8f9580ce213cfd64f56e86aea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744820400,
      "headline": "Abbott Labs Bracing for Tariffs as Profits Rise",
      "id": 133942562,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Labs boosted its earnings in the first quarter and hinted that its full-year guidance might have gotten a lift were it not for looming cost hikes from the recent tariff war.",
      "url": "https://finnhub.io/api/news?id=07cd7701c08de84256ccffcfdb178181affbe3c8f9580ce213cfd64f56e86aea"
    }
  },
  {
    "ts": null,
    "headline": "United Airlines & Abbott Labs earnings, Ackman's Hertz stake",
    "summary": "Brad Smith outlines some of the top stories on Wall Street in just 60 seconds on today's Market Minute. United Airlines (UAL) shares rise after reporting earnings results and providing investors with dual outlooks depending on the health of the US economy. Abbott Laboratories (ABT) stock rises after the medical supply company reported better-than-expected earnings results. Hertz (HTZ) shares surge after Bill Ackman-led Pershing Square Capital Management disclosed a large stake in the rental car company. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=78143db4e48bfd195571b1b16519f4b66a7ca66cc37596b3af494f11d3755a8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744819957,
      "headline": "United Airlines & Abbott Labs earnings, Ackman's Hertz stake",
      "id": 133935658,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Brad Smith outlines some of the top stories on Wall Street in just 60 seconds on today's Market Minute. United Airlines (UAL) shares rise after reporting earnings results and providing investors with dual outlooks depending on the health of the US economy. Abbott Laboratories (ABT) stock rises after the medical supply company reported better-than-expected earnings results. Hertz (HTZ) shares surge after Bill Ackman-led Pershing Square Capital Management disclosed a large stake in the rental car company. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=78143db4e48bfd195571b1b16519f4b66a7ca66cc37596b3af494f11d3755a8e"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT) Shares Skyrocket, What You Need To Know",
    "summary": "Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) jumped 5.4% in the morning session after the company reported decent first-quarter 2025 results with revenue in line, although its organic revenue fell slightly short of Wall Street's estimates. EPS in the quarter beat slightly, while full-year EPS guidance met expectations. The full-year sales outlook was also maintained, which was encouraging despite the uncertain macro backdrop.",
    "url": "https://finnhub.io/api/news?id=5d817c36d412225037a5f367a22da4680e0a0093f9bc5c964707a0778f62aa4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744819409,
      "headline": "Abbott Laboratories (ABT) Shares Skyrocket, What You Need To Know",
      "id": 133935659,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Shares of healthcare product and device company Abbott Laboratories (NYSE:ABT) jumped 5.4% in the morning session after the company reported decent first-quarter 2025 results with revenue in line, although its organic revenue fell slightly short of Wall Street's estimates. EPS in the quarter beat slightly, while full-year EPS guidance met expectations. The full-year sales outlook was also maintained, which was encouraging despite the uncertain macro backdrop.",
      "url": "https://finnhub.io/api/news?id=5d817c36d412225037a5f367a22da4680e0a0093f9bc5c964707a0778f62aa4d"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Nvidia, AMD Flag Looming Charges Tied to China Export Licenses; ASML Shares Fall on Sales Miss, Downbeat Guidance",
    "summary": "All three major US stock indexes were in the red at midday Wednesday, with the Nasdaq Composite down",
    "url": "https://finnhub.io/api/news?id=b7e59d18e063f8f1799fd2fe1333ff765db15f7a3287aa90a0ae991a9b480fd6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744819121,
      "headline": "Top Midday Stories: Nvidia, AMD Flag Looming Charges Tied to China Export Licenses; ASML Shares Fall on Sales Miss, Downbeat Guidance",
      "id": 133935513,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were in the red at midday Wednesday, with the Nasdaq Composite down",
      "url": "https://finnhub.io/api/news?id=b7e59d18e063f8f1799fd2fe1333ff765db15f7a3287aa90a0ae991a9b480fd6"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices",
    "summary": "Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices",
    "url": "https://finnhub.io/api/news?id=68df94c51cc2c20980833f001f82d858fe5a20a962f7066e0a6f98a86313a6df",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744819060,
      "headline": "Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices",
      "id": 133937157,
      "image": "",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=68df94c51cc2c20980833f001f82d858fe5a20a962f7066e0a6f98a86313a6df"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs Forecasts Tariff Impact of a ‘Few Hundred Million Dollars’",
    "summary": "Abbott Laboratories forecasts an impact of \"a few hundred million dollars\" this year from Trump administration tariffs, Chief Executive Robert Ford told analysts Wednesday.  The healthcare company sees the costs starting in the third quarter.  Ford told analysts it is too early to simply double the 2025 estimate for how tariffs might affect Abbott in future years, but the company can cover them in the near term.",
    "url": "https://finnhub.io/api/news?id=a31fa2f28556a4e6ec1ce320106127e6b5aa0252b206a6fa744760ca544dfcfd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744816792,
      "headline": "Abbott Labs Forecasts Tariff Impact of a ‘Few Hundred Million Dollars’",
      "id": 133935661,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories forecasts an impact of \"a few hundred million dollars\" this year from Trump administration tariffs, Chief Executive Robert Ford told analysts Wednesday.  The healthcare company sees the costs starting in the third quarter.  Ford told analysts it is too early to simply double the 2025 estimate for how tariffs might affect Abbott in future years, but the company can cover them in the near term.",
      "url": "https://finnhub.io/api/news?id=a31fa2f28556a4e6ec1ce320106127e6b5aa0252b206a6fa744760ca544dfcfd"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs sees tariffs costing ‘a few hundred million dollars’ this year",
    "summary": "Abbott Labs sees tariffs costing ‘a few hundred million dollars’ this year",
    "url": "https://finnhub.io/api/news?id=546c4c45df5d26246ff3ca849245abfad6e9de05d8130d2e66ffedd5444505a1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744816740,
      "headline": "Abbott Labs sees tariffs costing ‘a few hundred million dollars’ this year",
      "id": 133946284,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Abbott Labs sees tariffs costing ‘a few hundred million dollars’ this year",
      "url": "https://finnhub.io/api/news?id=546c4c45df5d26246ff3ca849245abfad6e9de05d8130d2e66ffedd5444505a1"
    }
  },
  {
    "ts": null,
    "headline": "Pre-Markets Open in The Red",
    "summary": "Pre-Markets Open in The Red",
    "url": "https://finnhub.io/api/news?id=ccbe71ab725ee2d5a515c4e401586425148828697d2052b943833d496c54e960",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744815240,
      "headline": "Pre-Markets Open in The Red",
      "id": 133935662,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Pre-Markets Open in The Red",
      "url": "https://finnhub.io/api/news?id=ccbe71ab725ee2d5a515c4e401586425148828697d2052b943833d496c54e960"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories stock pops on earnings beat",
    "summary": "Abbott Laboratories (ABT) stock is gaining after the healthcare tech company reported a first quarter earnings beat. Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani sits down with Madison Mills and Brad Smith on Morning Brief to discuss the earnings print and the latest developments in the healthcare sector. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
    "url": "https://finnhub.io/api/news?id=44f770eacd1fcc7b9b2596c991ad929f76fc64bee434969646c12fee44275df2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744815210,
      "headline": "Abbott Laboratories stock pops on earnings beat",
      "id": 133935663,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (ABT) stock is gaining after the healthcare tech company reported a first quarter earnings beat. Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani sits down with Madison Mills and Brad Smith on Morning Brief to discuss the earnings print and the latest developments in the healthcare sector. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
      "url": "https://finnhub.io/api/news?id=44f770eacd1fcc7b9b2596c991ad929f76fc64bee434969646c12fee44275df2"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories Maintains 2025 Outlook as First-Quarter Earnings Top Views",
    "summary": "Abbott Laboratories (ABT) affirmed its full-year outlook on Wednesday as the healthcare company repo",
    "url": "https://finnhub.io/api/news?id=f594aa9e0976ff812925770130c1f4dee04042ede0f60631ab28b76a7b4a7f8b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744814680,
      "headline": "Abbott Laboratories Maintains 2025 Outlook as First-Quarter Earnings Top Views",
      "id": 133935664,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (ABT) affirmed its full-year outlook on Wednesday as the healthcare company repo",
      "url": "https://finnhub.io/api/news?id=f594aa9e0976ff812925770130c1f4dee04042ede0f60631ab28b76a7b4a7f8b"
    }
  },
  {
    "ts": null,
    "headline": "IYH: Healthcare Dashboard For April",
    "summary": "IYH: Healthcare Dashboard For April",
    "url": "https://finnhub.io/api/news?id=ef60e7fe50c851812342eddac8f56058cf17e7e5c0696e76992c679d592b9289",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744814463,
      "headline": "IYH: Healthcare Dashboard For April",
      "id": 133936894,
      "image": "",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ef60e7fe50c851812342eddac8f56058cf17e7e5c0696e76992c679d592b9289"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations",
    "summary": "Abbott Labs posts first-quarter sales that missed analysts’ estimates but rose 4% from a year earlier.",
    "url": "https://finnhub.io/api/news?id=630b0893d2e4e305d8a96fc7c1104ec5c7c9f0414d1161eae9c38acafde701ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744813020,
      "headline": "Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations",
      "id": 133935665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Labs posts first-quarter sales that missed analysts’ estimates but rose 4% from a year earlier.",
      "url": "https://finnhub.io/api/news?id=630b0893d2e4e305d8a96fc7c1104ec5c7c9f0414d1161eae9c38acafde701ab"
    }
  },
  {
    "ts": null,
    "headline": "Abbott expects a ‘few hundred million’ in tariff costs in 2025",
    "summary": "CEO Robert Ford told investors the company had considered raising its earnings forecast for 2025, but decided to maintain it in light of the new tariffs.",
    "url": "https://finnhub.io/api/news?id=472b240c5482bf73528f1f1fe1e414fd63827758f59d67b5d975181f590fecc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744811566,
      "headline": "Abbott expects a ‘few hundred million’ in tariff costs in 2025",
      "id": 133942563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "CEO Robert Ford told investors the company had considered raising its earnings forecast for 2025, but decided to maintain it in light of the new tariffs.",
      "url": "https://finnhub.io/api/news?id=472b240c5482bf73528f1f1fe1e414fd63827758f59d67b5d975181f590fecc3"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs Clocks Q1 Profit Beat, CEO Says Diversification And Execution Enable Navigation During Uncertainty",
    "summary": "Abbott Laboratories (NYSE:ABT) on Wednesday reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. First-quarter sales increased 4% on a reported basis, 6.9% on an organic basis, or 8.3% when excluding COVID-19 testing-related sales. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09. “Once again, Abbott’s diversified business model delivered top-tie",
    "url": "https://finnhub.io/api/news?id=86dde14e87d43ffe227f76eef016bc124cfdd628c4677073914976dffc414402",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744811068,
      "headline": "Abbott Labs Clocks Q1 Profit Beat, CEO Says Diversification And Execution Enable Navigation During Uncertainty",
      "id": 133935666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) on Wednesday reported first-quarter sales of $10.36 billion, up 7.2% year over year, almost in line with the consensus of $10.40 billion. First-quarter sales increased 4% on a reported basis, 6.9% on an organic basis, or 8.3% when excluding COVID-19 testing-related sales. The U.S. MedTech giant reported adjusted EPS of $1.09, beating the consensus of $1.07 and the management guidance of $1.05-$1.09. “Once again, Abbott’s diversified business model delivered top-tie",
      "url": "https://finnhub.io/api/news?id=86dde14e87d43ffe227f76eef016bc124cfdd628c4677073914976dffc414402"
    }
  },
  {
    "ts": null,
    "headline": "Compared to Estimates, Abbott (ABT) Q1 Earnings: A Look at Key Metrics",
    "summary": "While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
    "url": "https://finnhub.io/api/news?id=5e49511130d339d329249847cb67b4c610a65678ac3f4ba17889a51efd93229e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744810208,
      "headline": "Compared to Estimates, Abbott (ABT) Q1 Earnings: A Look at Key Metrics",
      "id": 133935667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",
      "url": "https://finnhub.io/api/news?id=5e49511130d339d329249847cb67b4c610a65678ac3f4ba17889a51efd93229e"
    }
  },
  {
    "ts": null,
    "headline": "Nvidia, ASML, Abbott Labs: Stocks to watch today",
    "summary": "U.S. stock futures moved lower Wednesday as investors braced for another wave of geopolitical and earnings headlines. S&P 500 futures were down 0.5%, the Dow hovered near flat, and Nasdaq futures dropped more than 1%.",
    "url": "https://finnhub.io/api/news?id=8f5c30fdb31f0cc761dc1d9296c391a04e954ca0ff7abcfa508841ca42833f44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744809669,
      "headline": "Nvidia, ASML, Abbott Labs: Stocks to watch today",
      "id": 133935668,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "U.S. stock futures moved lower Wednesday as investors braced for another wave of geopolitical and earnings headlines. S&P 500 futures were down 0.5%, the Dow hovered near flat, and Nasdaq futures dropped more than 1%.",
      "url": "https://finnhub.io/api/news?id=8f5c30fdb31f0cc761dc1d9296c391a04e954ca0ff7abcfa508841ca42833f44"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Bounds Off 50-Day Line, Shrugging Off Covid Test Malaise",
    "summary": "Abbott stock jumped after the market opened Wednesday despite a mixed first-quarter report thanks to light sales of its Covid tests.",
    "url": "https://finnhub.io/api/news?id=d6133cd11c220a6392042f3d318eb0aec2f82a2ecba103a2a3469b3a74b8aa78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744808359,
      "headline": "Abbott Bounds Off 50-Day Line, Shrugging Off Covid Test Malaise",
      "id": 133935669,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott stock jumped after the market opened Wednesday despite a mixed first-quarter report thanks to light sales of its Covid tests.",
      "url": "https://finnhub.io/api/news?id=d6133cd11c220a6392042f3d318eb0aec2f82a2ecba103a2a3469b3a74b8aa78"
    }
  },
  {
    "ts": null,
    "headline": "Abbott (ABT) Q1 Earnings Beat Estimates",
    "summary": "Abbott (ABT) delivered earnings and revenue surprises of 1.87% and 0.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=07e897e6b00fb6537a5db07f08bee0ec0370a4501fc553fb7a23755b59300d76",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744807502,
      "headline": "Abbott (ABT) Q1 Earnings Beat Estimates",
      "id": 133935670,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (ABT) delivered earnings and revenue surprises of 1.87% and 0.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=07e897e6b00fb6537a5db07f08bee0ec0370a4501fc553fb7a23755b59300d76"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Stock Gains 5.8% in 3 Months: Here's How to Play it",
    "summary": "HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.",
    "url": "https://finnhub.io/api/news?id=a8de60d3fdfd664a18a797267d0ae0f7bae28090dfcb691de803def3fe9e9ddd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744807380,
      "headline": "Hims & Hers Stock Gains 5.8% in 3 Months: Here's How to Play it",
      "id": 133935671,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "HIMS is enhancing offerings and expanding its health and wellness products and services to solidify its footing. However, macro challenges are likely to hurt its performance.",
      "url": "https://finnhub.io/api/news?id=a8de60d3fdfd664a18a797267d0ae0f7bae28090dfcb691de803def3fe9e9ddd"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs Profit Jumps on Gains in Nutrition, Medical Devices",
    "summary": "Abbott Labs recorded higher earnings and revenue in the first quarter as strong demand for its nutritional products and medical devices offset weakness in other segments.",
    "url": "https://finnhub.io/api/news?id=c2e6e2020d3463c991d9a77e7d7b76f31fa7272809fe6974cc6a74ffd387b6f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744806180,
      "headline": "Abbott Labs Profit Jumps on Gains in Nutrition, Medical Devices",
      "id": 133935672,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Labs recorded higher earnings and revenue in the first quarter as strong demand for its nutritional products and medical devices offset weakness in other segments.",
      "url": "https://finnhub.io/api/news?id=c2e6e2020d3463c991d9a77e7d7b76f31fa7272809fe6974cc6a74ffd387b6f4"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs Bracing for Tariffs as Profits Rise -- Update",
    "summary": "By Dean Seal Abbott Labs boosted its earnings in the first quarter and hinted that its full-year guidance might have gotten a lift were it not for looming cost hikes from the recent tariff war....",
    "url": "https://finnhub.io/api/news?id=483feafe3c7188637d7e90a641b41bfdfe9ba30e94e5ccd08bf858246526b76f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744806140,
      "headline": "Abbott Labs Bracing for Tariffs as Profits Rise -- Update",
      "id": 133935255,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "By Dean Seal Abbott Labs boosted its earnings in the first quarter and hinted that its full-year guidance might have gotten a lift were it not for looming cost hikes from the recent tariff war....",
      "url": "https://finnhub.io/api/news?id=483feafe3c7188637d7e90a641b41bfdfe9ba30e94e5ccd08bf858246526b76f"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Retail Sales Defy Expectations Amid Consumer Confidence Distress",
    "summary": "Consumer confidence may be tumbling, but the willingness to spend didnât crumble last month.",
    "url": "https://finnhub.io/api/news?id=25044deedf05a43e270a38e3074dfa5733bc664f84332ebac8bbb05a2ecdcc60",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744804500,
      "headline": "Wall Street Lunch: Retail Sales Defy Expectations Amid Consumer Confidence Distress",
      "id": 133935183,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/672154853/image_672154853.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Consumer confidence may be tumbling, but the willingness to spend didnât crumble last month.",
      "url": "https://finnhub.io/api/news?id=25044deedf05a43e270a38e3074dfa5733bc664f84332ebac8bbb05a2ecdcc60"
    }
  },
  {
    "ts": null,
    "headline": "Abbott backs profit forecast, to invest $500 million in US amid tariffs",
    "summary": "Medical device maker Abbott Laboratories maintained its annual profit forecast on Wednesday and said it expected the U.S. tariffs to hit earnings by a few hundred million dollars. ...",
    "url": "https://finnhub.io/api/news?id=2eae9d93093f29c468fa66e597b412346bb273f07d5d00bb7001d8942dc00aba",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744804406,
      "headline": "Abbott backs profit forecast, to invest $500 million in US amid tariffs",
      "id": 133935100,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "Medical device maker Abbott Laboratories maintained its annual profit forecast on Wednesday and said it expected the U.S. tariffs to hit earnings by a few hundred million dollars. ...",
      "url": "https://finnhub.io/api/news?id=2eae9d93093f29c468fa66e597b412346bb273f07d5d00bb7001d8942dc00aba"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (NYSE:ABT) Posts Q1 Sales In Line With Estimates",
    "summary": "Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 4% year on year to $10.36 billion. Its non-GAAP profit of $1.09 per share was 1.7% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=d1e9f188b801b5c57fddd4f639208fa7aa054f344e097d6fb0bae9dff16accfb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744803839,
      "headline": "Abbott Laboratories (NYSE:ABT) Posts Q1 Sales In Line With Estimates",
      "id": 133935673,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 4% year on year to $10.36 billion. Its non-GAAP profit of $1.09 per share was 1.7% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=d1e9f188b801b5c57fddd4f639208fa7aa054f344e097d6fb0bae9dff16accfb"
    }
  },
  {
    "ts": null,
    "headline": "Abbott: Q1 Earnings Snapshot",
    "summary": "The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.07 per share. The maker of infant formula, medical devices and drugs posted revenue of $10.36 billion in the period, which did not meet Street forecasts.",
    "url": "https://finnhub.io/api/news?id=183721b17f472555d4605af4b59aba5d03ad490851f88277d42560d2e0f66c8a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744803524,
      "headline": "Abbott: Q1 Earnings Snapshot",
      "id": 133935674,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.07 per share. The maker of infant formula, medical devices and drugs posted revenue of $10.36 billion in the period, which did not meet Street forecasts.",
      "url": "https://finnhub.io/api/news?id=183721b17f472555d4605af4b59aba5d03ad490851f88277d42560d2e0f66c8a"
    }
  },
  {
    "ts": null,
    "headline": "Robust Specialty Diagnostics Segment Likely to Aid TMO's Q1 Earnings",
    "summary": "Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's first-quarter 2025 performance.",
    "url": "https://finnhub.io/api/news?id=e2a6540224cab3ec1a65122c821b5a3f8407e49f3e327211bae8066685b9c082",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744803120,
      "headline": "Robust Specialty Diagnostics Segment Likely to Aid TMO's Q1 Earnings",
      "id": 133935676,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Strength in Analytical Instruments and Specialty Diagnostics segments is likely to have driven Thermo Fisher's first-quarter 2025 performance.",
      "url": "https://finnhub.io/api/news?id=e2a6540224cab3ec1a65122c821b5a3f8407e49f3e327211bae8066685b9c082"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance",
    "summary": "Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2025.",
    "url": "https://finnhub.io/api/news?id=f3f9b2e12a6eb876e1eb706f452f6277b0ca4caaa03cb514b0b7fb00cf84ba93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744803000,
      "headline": "Abbott Reports First-Quarter 2025 Results and Reaffirms Full-Year Guidance",
      "id": 133935677,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2025.",
      "url": "https://finnhub.io/api/news?id=f3f9b2e12a6eb876e1eb706f452f6277b0ca4caaa03cb514b0b7fb00cf84ba93"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT) Q1 2025 Earnings Call Transcript",
    "summary": "Abbott Laboratories (NYSE:ABT) Q1 2025 Earnings Conference Call April 16, 2025 9:00 AM ETCompany ParticipantsMike Comilla - VP, IRRobert Ford - Chairman and...",
    "url": "https://finnhub.io/api/news?id=210ac9a52647d913946b6f904f31457abd269cc21ba378cf1d20972a16ce569a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744802657,
      "headline": "Abbott Laboratories (ABT) Q1 2025 Earnings Call Transcript",
      "id": 133935022,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "Abbott Laboratories (NYSE:ABT) Q1 2025 Earnings Conference Call April 16, 2025 9:00 AM ETCompany ParticipantsMike Comilla - VP, IRRobert Ford - Chairman and...",
      "url": "https://finnhub.io/api/news?id=210ac9a52647d913946b6f904f31457abd269cc21ba378cf1d20972a16ce569a"
    }
  },
  {
    "ts": null,
    "headline": "Abbott maintains profit forecast, invests $500 million in US amid tariffs",
    "summary": "Abbott Laboratories maintained its annual profit forecast on Wednesday and announced $500 million in manufacturing and research investments in the U.S. in the face of tariff-induced uncertainty. ...",
    "url": "https://finnhub.io/api/news?id=a24a0795f71e229c4a57091e6a4a0b8f9bc90e4bdf717aa20139cbdec9e72897",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744795854,
      "headline": "Abbott maintains profit forecast, invests $500 million in US amid tariffs",
      "id": 133934419,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "Abbott Laboratories maintained its annual profit forecast on Wednesday and announced $500 million in manufacturing and research investments in the U.S. in the face of tariff-induced uncertainty. ...",
      "url": "https://finnhub.io/api/news?id=a24a0795f71e229c4a57091e6a4a0b8f9bc90e4bdf717aa20139cbdec9e72897"
    }
  },
  {
    "ts": null,
    "headline": "Abbott maintains profit forecast, plans new US investments amid tariff risks",
    "summary": "Abbott Laboratories maintained its annual profit forecast on Wednesday and announced $500 million in investments towards U.S. manufacturing and research in the face of tariff-induced uncertainty. ...",
    "url": "https://finnhub.io/api/news?id=d6faba0a1ea2669ef691ecf3f763720ab0d2f40f8a5c18710779f397673d318d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744792483,
      "headline": "Abbott maintains profit forecast, plans new US investments amid tariff risks",
      "id": 133934137,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "Abbott Laboratories maintained its annual profit forecast on Wednesday and announced $500 million in investments towards U.S. manufacturing and research in the face of tariff-induced uncertainty. ...",
      "url": "https://finnhub.io/api/news?id=d6faba0a1ea2669ef691ecf3f763720ab0d2f40f8a5c18710779f397673d318d"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices",
    "summary": "By Dean Seal Abbott Labs recorded higher earnings and revenue in the first quarter as strong demand for its nutritional products and medical devices offset weakness in other segments. The...",
    "url": "https://finnhub.io/api/news?id=ca467dd924219b67aea32a959fe8e3cce19c5304ba9391d132b9acc84a1fb0cd",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744791308,
      "headline": "Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices",
      "id": 133934003,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "By Dean Seal Abbott Labs recorded higher earnings and revenue in the first quarter as strong demand for its nutritional products and medical devices offset weakness in other segments. The...",
      "url": "https://finnhub.io/api/news?id=ca467dd924219b67aea32a959fe8e3cce19c5304ba9391d132b9acc84a1fb0cd"
    }
  },
  {
    "ts": null,
    "headline": "Abbott beats quarterly profit estimate on strong demand for diabetes devices",
    "summary": "Abbott Laboratories beat Wall Street estimates for first-quarter profit on Wednesday, buoyed by strong demand for diabetes care and other medical devices. The company also maintained its...",
    "url": "https://finnhub.io/api/news?id=76c9bdf9f04920ca3af9714c3fa32fa09a4ba43bccc8a27f132f0795b1619355",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744789560,
      "headline": "Abbott beats quarterly profit estimate on strong demand for diabetes devices",
      "id": 133933752,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "Abbott Laboratories beat Wall Street estimates for first-quarter profit on Wednesday, buoyed by strong demand for diabetes care and other medical devices. The company also maintained its...",
      "url": "https://finnhub.io/api/news?id=76c9bdf9f04920ca3af9714c3fa32fa09a4ba43bccc8a27f132f0795b1619355"
    }
  },
  {
    "ts": null,
    "headline": "Abbott beats quarterly profit estimate on strong medical device demand",
    "summary": "Abbott Laboratories beat Wall Street estimates for first-quarter profit on Wednesday, buoyed by strong demand for diabetes care and other medical devices. The company also maintained its full-year...",
    "url": "https://finnhub.io/api/news?id=e60b3d8af567d29920976879cca9ad5f1d70d017d42ff7c8853fb8fa5e291d83",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744788802,
      "headline": "Abbott beats quarterly profit estimate on strong medical device demand",
      "id": 133933700,
      "image": "",
      "related": "ABT",
      "source": "Finnhub",
      "summary": "Abbott Laboratories beat Wall Street estimates for first-quarter profit on Wednesday, buoyed by strong demand for diabetes care and other medical devices. The company also maintained its full-year...",
      "url": "https://finnhub.io/api/news?id=e60b3d8af567d29920976879cca9ad5f1d70d017d42ff7c8853fb8fa5e291d83"
    }
  },
  {
    "ts": null,
    "headline": "Financial stocks dominate earnings slate",
    "summary": "Financial stocks dominate earnings slate",
    "url": "https://finnhub.io/api/news?id=dc362b5b777b10fb5a5ce041de7e68fe7d1be24dddccf0c32554747b8993e6ac",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744775759,
      "headline": "Financial stocks dominate earnings slate",
      "id": 133946287,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Financial stocks dominate earnings slate",
      "url": "https://finnhub.io/api/news?id=dc362b5b777b10fb5a5ce041de7e68fe7d1be24dddccf0c32554747b8993e6ac"
    }
  }
]